A carregar...
Biological challenges of BRAF inhibitor therapy
Activating mutations in BRAF, a constituent of the map kinase pathway, were first discovered as being most prevalent in melanoma in 2002. Only recently have potent and selective, orally available inhibitors of BRAF emerged for clinical testing and demonstrated clear evidence of tumor regression in t...
Na minha lista:
| Publicado no: | Mol Oncol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5528282/ https://ncbi.nlm.nih.gov/pubmed/21393075 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2011.01.005 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|